Goldman Sachs
DRUG

Goldman Sachs’s Bright Minds Biosciences DRUG Stock Holding History

Goldman Sachs’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.43M Buy
74,369
+25,822
+53% +$2.08M ﹤0.01% 3617
2025
Q4 		$3.79M Buy
+48,547
New +$3.24M ﹤0.01% 4004
2025
Q2 		– Sell
-22,222
Closed -$802K – 6152
2025
Q1 		$802K Buy
+22,222
New +$813K ﹤0.01% 4850

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Goldman Sachs's DRUG Position: Q1 2026 in Review

Goldman Sachs increased its Bright Minds Biosciences (DRUG) stake by 53% in Q1 2026, buying an estimated $2.08M and bringing the position to 74,369 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Goldman Sachs first reported a position in DRUG in Q1 2025 and has held it in 3 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Goldman Sachs held 74,369 shares of Bright Minds Biosciences worth $5.43M as of Q1 2026.
  • Goldman Sachs bought 25,822 Bright Minds Biosciences shares in Q1 2026, an estimated $2.08M.
  • Bright Minds Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3617 holding.
  • Goldman Sachs first reported a position in Bright Minds Biosciences in Q1 2025 and has held it in 3 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.